The effect of Oral BUtyrate on human Glucose and brownfAT metabolism: The OBUGAT study
Completed
- Conditions
- insulin sensitivitybrown adipose tissue
- Registration Number
- NL-OMON27355
- Lead Sponsor
- AMC-UvA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
Healthy lean male volunteers (N=10, BMI 19-25 kg/m2) and obese insulin resistant male volunteers (N=10) matched for age will be recruited and tested for BAT activity and insulin sensitivity before and after oral butyrate treatment.
Exclusion Criteria
- Any Medication or probiotic use
- Smoking
- Participation in a research protocol involving radiation exposure in the last 2 years.
- eGFR <60 ml/min
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary objective: To investigate whether butyrate influences the metabolic activity of BAT (as assessed with a FDG-PET CT scan) in relation to hepatic and peripheral insulin sensitivity (two step hyperinsulinemic normoglycemic clamp).
- Secondary Outcome Measures
Name Time Method Secondary Objectives: <br>-To determine whether differences in resting energy expenditure during thermoneutral conditions correlate with the metabolic BAT activity before and after butyrate treatment.<br>- To determine if fecal gutmicrobiota and fecal energy excretion are altered upon oral butyrate treatment. <br>-Changes in expression of genes involved in insulin phosphorylation signalling pathways, inflammation and lipid synthesis in subcutaneous fat upon oral butyrate supplementation.<br>- changes in plasma (monocyte) and subcutaneous adipose tissue inflammatory markers upon 4 weeks of butyrate treatment.